Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3921]
News [11377]
Articles [47]
Editorials [10]
Conferences [197]
elearning [4]
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed...
Prof Marion Subklewe - University of Munich, Munich, Germany
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML ( Prof Marion Subklewe - University of Munich, Munich, Germany )
6 Dec 2018
KRd versus VRd in patients with newly diagnosed multiple myeloma
Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA
KRd versus VRd in patients with newly diagnosed multiple myeloma ( Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA )
6 Dec 2018
Researchers identify mutation that causes resistance to venetoclax in CLL...
Dr Piers Blombery - University of Melbourne, Melbourne, Australia
Researchers identify mutation that causes resistance to venetoclax in CLL patients ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )
6 Dec 2018
Daratumumab increases PFS in patients with transplant-ineligible multiple...
Prof Thierry Facon - Hôpital Claude Huriez, Lille, France
Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )
6 Dec 2018
Ibrutinib and rituximab provides superior PFS and OS compared to FCR for...
Dr Tait Shanafelt - Standford University, Stanford, USA
Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL ( Dr Tait Shanafelt - Standford University, Stanford, USA )
6 Dec 2018
Resistance mechanisms to venetoclax in patients with progressive CLL
Dr Piers Blombery - University of Melbourne, Melbourne, Australia
Resistance mechanisms to venetoclax in patients with progressive CLL ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )
4 Dec 2018
Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy
Dr Alok Khorana - Cleveland Clinic, Cleveland, USA
Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy ( Dr Alok Khorana - Cleveland Clinic, Cleveland, USA )
4 Dec 2018
Ibrutinib-based therapy superior for younger patients with previously untreated...
Dr Tait Shanafelt - Stanford University, Stanford, USA
Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care ( Dr Tait Shanafelt - Stanford University, Stanford, USA )
4 Dec 2018
Daratumumab found to increase PFS in patients with transplant-ineligible newly...
Prof Thierry Facon - Hôpital Claude Huriez, Lille, France
Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )
4 Dec 2018
The importance of NF-kB pathway in myeloma
Dr Nizar Bahlis - University of Calgary, Calgary, Canada
The importance of NF-kB pathway in myeloma ( Dr Nizar Bahlis - University of Calgary, Calgary, Canada )
3 Dec 2018
Multiple myeloma highlights and more from ASH 2018
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Multiple myeloma highlights and more from ASH 2018 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
3 Dec 2018
Results of the Beat AML umbrella study for previously untreated acute myeloid...
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )
3 Dec 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation